同源异型盒基因5在急性髓细胞性白血病中表达的研究

目的 研究同源异型盒基因5 (HOXA5)在急性髓细胞性白血病(AML)中表达情况. 方法 使用荧光定量聚合酶链式反应法检测108例AML中HOXA5表达,分析HOXA5表达与AML的相关性.结果 HOXA5在初诊AML与正常人群中,表达差异无统计学意义(P>0.05);在原发性AML和继发性AML患者中,表达差异无统计学意义(P>0.05);在初次诱导治疗完全缓解和未缓解患者中,表达差异有统计学意义(P<0.05);在年龄≥60岁和<60岁患者中,差异无统计学意义(P>0.05);男性与女性AML患者相比,HOXA5表达差异有统计学意义(P<0.05).HOXA5表达与CD34、HLA-DR、CD33、WBC计数、LDH的无相关性(P>0.05),与骨髓原始细胞数有相关性(P<0.05).结论 HOXA5高表达可造成AML较差的治疗反应.

Expression of HOXA5 in adults with acute meloid leukemia

Objective To investigate the clinical significance of Homeobox gene 5 (HOXA5) expression in adults with acute meloid leukemia. Methods The expression of HOXA5 genes of bone marrow samples from 108 newly diagnosed AML patients were examined by realtime quantitative polymerase chain reaction (RTQ-PCR) assay. Statistical ways were used to analyze the relationship between the treatment and prognostic factors and the expression of HOXA5. Results There was no significant difference between the untreated AML group and the normal group(P>0.05), primary-AML and secondary-AML (P>0.05), and the 60 years old-higher and 60 years old-lower(P=0.18) about the HOXA5 expression. The expression of HOXA5 was lower in complete remission group than in non-remission group in one standard induction therapy(P<0.05). In male and female groups statistically significant difference was found in the expression of HOXA5 (P<0.05). HOXA5 expression had no connection with CD34,HLA-DR,CD33,counts of WBC and LDH of the patients (P>0.05). Bone marrow progenitor cells had statistical significance in the expression of HOXA5(P<0.05). Conclusion The over expression of HOXA5 may result in poor treatment response in AML.